Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules

Statistics in Medicine

Volumn 35, Issue 22, 2016, Pages 3907-3922

  Robertson, David S ^a   Prevost, A Toby ^b   Bowden, Jack ^a,c  

^a MRC BIOSTATISTICS UNIT   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

adaptive seamless designs; phase II III clinical trials; treatment selection; uniformly minimum variance unbiased estimator

Indexed keywords

CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXPERIMENTAL THERAPY; HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL;

EID: 84985992292     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6974     Document Type: Article

References (22)

1. Barnes PJ, Pocock SJ, Magnussen H, Iqbal A, Kramer B, Higgins M, Lawrence D. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology & Therapeutics 2010; 23(3): 165–171.
2. Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, Linssen G, Tebbe U, Schroeder R, Tiemann R, Machnig T, Neuhaus KL. The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. Journal of the American College of Cardiology 2001; 38(6): E1644–E1650.
3. Schmoll H, Cunnighmam DAS, Krapetis C, Rougier P, Koski SPB, Mookerjee B, Robertson J, van Cutsem E. mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (MCRC): a randomised, doubleblind, phase II/III study (HORIZON III). Annals of Oncology 2010; 21(suppl 8): viii189–viii224.
4. EMA. CHMP reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design 29 March 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf.
5. FDA. Draft guidance for industry adaptive design clinical tials for drugs and biologics 29 March 2016. http://www.fda.gov/downloads/Drugs/../Guidances/ucm201790.pdf.
6. Bauer P, Koenig F, Brannath W, Posch M. Selection and bias – two hostile brothers. Statistics in Medicine 2010; 29(1): 1–13.
7. Kimani PK, Todd S, Stallard N. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility. Statistics in Medicine 2013; 32(17): 2893–2910.
8. Cohen A, Sackrowitz HB. Two stage conditionally unbiased estimators of the selected mean. Statistics & Probability Letters 1989; 8(3): 273–278.
9. Bowden J, Brannath W, Glimm E. Empirical Bayes estimation of the selected treatment mean for two-stage drop-the-loser trials: a meta-analytic approach. Statistics in Medicine 2014; 33(3): 388–400.
10. Bowden J, Glimm E. Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal 2008; 50(4): 515–527.
11. Bowden J, Glimm E. Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials. Biometrical Journal 2014; 56(2): 332–349.
12. Carreras M, Brannath W. Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection. Statistics in Medicine 2013; 32(10): 1677–1690.
13. Bretz F, Schmidli H, König F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biometrical Journal 2006; 48(4): 623–634.
14. Stallard N, Todd S. Seamless phase II/III designs. Statistical Methods in Medical Research 2011; 20(6): 623–634.
15. Robertson DS, Prevost AT, Bowden J. Accounting for selection and correlation in the analysis of two-stage genome-wide association studies. Biostatistics. Advance online publication. DOI: 10.1093/biostatistics/kxw012.
16. Bretz F, Koenig F, Brannath W, Glimm E, Posch M. Adaptive designs for confirmatory clinical trials. Statistics in Medicine 2009; 28: 1181–1217.
17. Hochberg Y, Tamhane AC. Multiple Comparison Procedures. Wiley: New York, 1987.
18. Marcus R, Eric P, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63(3): 655–660.
19. Alosh M, Bretz F, Huque M. Advanced multiplicity adjustment methods in clinical trials. Statistics in Medicine 2013; 33: 693–713.
20. Bowden J, Dudbridge F. Unbiased estimation of odds ratios: combining genomewide association scans with replication studies. Genetic Epidemiology 2009; 33(5): 406–418.
21. Pepe MS, Feng Z, Longton G, Koopmeiners J. Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. Statistics in Medicine 2009; 28: 762–779.
22. Sampson AR, Sill MW. Drop-the-losers design: normal case. Biometrical Journal 2005; 47(3): 257–268.